Good evening :)
$
₹
Redhill Biopharma Ltd

Redhill Biopharma Ltd

RDHL

NASDAQ
Asset Logo

Redhill Biopharma Ltd

RDHL

NASDAQ
$0.443.28% (+0.01)
$
₹
$0.443.28% (+0.01)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Micro Cap

With a market cap of $3.8M the stock is ranked 6019

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.01
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Based on consolidated analysts reports

?

Buy, Sell and Hold recommendations are not available

Price Upside

—

Earnings Growth

—

Rev. Growth

—

Company Profile

Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
45.74
45.74
1Y Return
47.62%
47.62%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
41.93
41.93
1Y Return
47.33%
47.33%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
151.87
151.87
1Y Return
74.12%
74.12%
Buy Reco %
67.85
67.85
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
31.48
31.48
1Y Return
29.02%
29.02%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.73
26.73
1Y Return
14.37%
14.37%
Buy Reco %
75.00
75.00
Compare with Peers

Forecast

Forecast

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

Financials

Financials

Income

Balance Sheet

Cash Flow

-6.1
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue1.281.282.73-2.032.03----
Net Income-1.54-1.54-2.59--2.06-2.06----6.10
Net Profit Margin-120.06%-120.06%-94.68%--101.32%-101.32%----
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Redhill Biopharma Ltd -1.010
Eli Lilly and Company45.7431.171.32
Johnson & Johnson41.937.852.99
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare RDHL with any stock or ETF
Compare RDHL with any stock or ETF
Comparing from
RDHL
LLY
JNJ
Loading...

Frequently asked questions

  1. Redhill Biopharma Ltd (RDHL) share price today is $0.44 as of November 6, 2026 at 11:22 PM IST. The stock touched a day high of $0.44 and a day low of $0.43.

  2. Redhill Biopharma Ltd stock trades on NASDAQ under the ticker symbol RDHL.

  3. Redhill Biopharma Ltd's market capitalization is $3.75M as of November 6, 2026 at 11:22 PM IST.

  4. Redhill Biopharma Ltd's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Redhill Biopharma Ltd's price-to-book (P/B) ratio is 1.01 as of November 6, 2026.

  6. Yes, You can buy Redhill Biopharma Ltd shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Redhill Biopharma Ltd shares in three steps: 1. Search Redhill Biopharma Ltd on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Redhill Biopharma Ltd trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Redhill Biopharma Ltd (RDHL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 22.7272 shares at the current price of $0.44.

Loading...